Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MROH7-TTC4 readthrough is a non-coding RNA gene resulting from a natural transcriptional readthrough event between the MROH7 and TTC4 loci on chromosome 1. This RNA is subject to alternative splicing, producing several transcript variants that are generally candidates for nonsense-mediated mRNA decay and are therefore unlikely to encode for a protein[1][2]. Functional annotation is limited, with minimal evidence for a direct biological role. The locus has been referenced in research examining vascular endothelial cell autophagy: specifically, regulation of its expression by upstream proteins (such as annexin A7) may indirectly influence processes like apoptosis in vascular endothelial cells, but its own mechanistic contribution remains unclear[3]. Currently, MROH7-TTC4 is not considered a druggable therapeutic target, a receptor, enzyme, or member of classical protein families. No disease associations, biomarkers, or drug interactions are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MROH7-TTC4 readthrough RNA (NMD candidate) (MROH7-TTC4).